Search company, investor...

Embera NeuroTherapeutics

emberaneuro.com

Founded Year

2005

Stage

Grant - VI | Alive

Total Raised

$43.48M

About Embera NeuroTherapeutics

Embera NeuroTherapeutics is a clinical stage pharmaceutical company developing treatments for to potentially treat a range of addictions located in the greater Boston, MA area.

Headquarters Location

365 Boston Post Road Suite 212

Sudbury, Massachusetts, 01776,

United States

978-579-4156

Missing: Embera NeuroTherapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Embera NeuroTherapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Embera NeuroTherapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Embera NeuroTherapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Embera NeuroTherapeutics Patents

Embera NeuroTherapeutics has filed 8 patents.

The 3 most popular patent topics include:

  • Glucocorticoids
  • Anxiolytics
  • Benzodiazepines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/12/2018

11/23/2021

Glucocorticoids, Pregnanes, Progestogens, Diketones, Prodrugs

Grant

Application Date

3/12/2018

Grant Date

11/23/2021

Title

Related Topics

Glucocorticoids, Pregnanes, Progestogens, Diketones, Prodrugs

Status

Grant

Latest Embera NeuroTherapeutics News

GABA Receptor Agonists Drug Market Research Report 2022: Comprehensive Insights About 25+ Companies and 25+ Pipeline Drugs - ResearchAndMarkets.com

Feb 10, 2022

This "GABA Receptor Agonists - Pipeline Insight, 2022" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in GABA Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The assessment part of the report embraces, in depth GABA Receptor Agonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, GABA Receptor Agonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence GABA Receptor Agonists R&D. The therapies under development are focused on novel approaches to treat/improve GABA Receptor Agonists. GABA Receptor Agonists Emerging Drugs Chapters This segment of the GABA Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. GABA Receptor Agonists Emerging Drugs Ganaxolone: Marinus Pharmaceuticals Ganaxolone, a positive allosteric modulator of GABAA receptors, is an investigational product being developed in intravenous and oral formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone exhibits anti-seizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. In August 2021, Marinus Pharmaceuticals announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of its lead product candidate ganaxolone, to treat seizures associated with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy. EMB-001: Embera NeuroTherapeutics EMB-001 is a patented combination product comprised of two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiological responses to stress in addiction. It is being developed by Embera NeuroTherapeutics and is currently in Phase II/III stage of development for the treatment of Smoking Cessation and Tobacco Use Disorder. GABA Receptor Agonists: Therapeutic Assessment This segment of the report provides insights about the different GABA Receptor Agonists drugs segregated based on following parameters that define the scope of the report. Major Players in GABA Receptor Agonists There are approx. 25+ key companies which are developing the therapies for GABA Receptor Agonists. The companies which have their GABA Receptor Agonists drug candidates in the most advanced stage, i.e. Pre-registration include, Marinus Pharmaceuticals. Key Questions How many GABA Receptor Agonists drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of GABA Receptor Agonists? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the GABA Receptor Agonists therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for GABA Receptor Agonists and their status? What are the key designations that have been granted to the emerging drugs? Key Players Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type

Embera NeuroTherapeutics Frequently Asked Questions (FAQ)

  • When was Embera NeuroTherapeutics founded?

    Embera NeuroTherapeutics was founded in 2005.

  • Where is Embera NeuroTherapeutics's headquarters?

    Embera NeuroTherapeutics's headquarters is located at 365 Boston Post Road, Sudbury.

  • What is Embera NeuroTherapeutics's latest funding round?

    Embera NeuroTherapeutics's latest funding round is Grant - VI.

  • How much did Embera NeuroTherapeutics raise?

    Embera NeuroTherapeutics raised a total of $43.48M.

  • Who are the investors of Embera NeuroTherapeutics?

    Investors of Embera NeuroTherapeutics include National Institute on Drug Abuse, Rose Research Center, Louisiana Funds, BVM Capital, Keiretsu Capital and 5 more.

  • Who are Embera NeuroTherapeutics's competitors?

    Competitors of Embera NeuroTherapeutics include Humanetics, Evotec SE, Zyla Life Sciences, Asteres, Vasopharm, Intarcia Therapeutics, Tarsa Therapeutics, Patheon, Ikaria, Ardelyx and 19 more.

Compare Embera NeuroTherapeutics to Competitors

N
NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

V
Vasopharm

Vasopharm develops therapeutics for acute inflammatory central nervous system conditions by targeting nitric oxide signaling pathways. The company focuses on drug development in central nervous system (CNS) niche indications with a high unmet medical need. It has taken a small molecule (VAS203) targeting pathological nitric oxide (NO) production and signaling from discovery to a pivotal clinical trial.

C
Cenes

The company is engaged in developing and commercializing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

J
JadoLabs

JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.